Search results
Results from the WOW.Com Content Network
In this large national contemporary cohort of men undergoing radical prostatectomy for localized prostate cancer, we estimated long-term outcomes for BCR, metastasis, prostate cancer-specific and overall 10-year survival. We found the cumulative incidence of BCR after radical prostatectomy was 28%.
Men aged less than 49 and more than 80 years old have the lowest 10-year survival rate. Those aged less than 49 years old had a 95.6% 10-year survival rate, while those aged more than 80 years old had an 82.7% 10-year survival rate.
The overall prognosis for prostate cancer is among the best of all cancers. It’s important to keep in mind that survival rates and likelihood of recurrence are based on averages and won’t necessarily reflect any individual patient outcome. The prognosis for prostate cancer depends on many factors.
The 10-year relative survival rate is 98%. Ten years after their prostate cancer diagnosis, they're only 2% less likely to be alive than anyone else. The relative 15-year survival rate is...
Conclusions: On average, we found a man undergoing radical prostatectomy for localized prostate cancer can expect about a 1 in 4 chance of biochemical recurrence. Of men with BCR, we identified a 1 in 10 chance of developing metastases, surviving nearly 9 years after incident metastasis.
For localized prostate cancer, 10-year relative survival was 100%. Ten-year relative survival for regional, distant, and unknown stage was 96.1%, 18.5%, and 78.1%, respectively. For distant stage prostate cancer, 10-year relative survival was highest for ages 60–64 years (21.8%) and was <20% for ages <55 and ≥70 years.
From the date of diagnosis, prostatectomy patients experienced an overall survival rate of 15.7 years, which is closest to the expected survival of 16.2 years. Approximately 75% of prostatectomy outcomes were progression free for 10.6 years or greater.
Moreover, up to 53% of patients with a tumor not confined to the prostate remain free of postoperative recurrence in the long term, and with careful selection of patients the 10-year overall survival rate is between 58% and 89%, depending on the risk constellation.
Based on the natural history of localized prostate cancer, the life expectancy (LE) of men treated with either radical prostatectomy (RP) or definitive external-beam radiotherapy (EBRT) should exceed 10 years.
Overall, the five-year and 10-year relative survival rates for prostate cancer in the United States are close to 100 percent.